A clinical study may open a new approach to childhood peanut allergies.
If your child is allergic to peanuts and 6 to 17 years old, ask your doctor about a clinical study evaluating the safety and efficacy of investigational products in peanut allergy.
Dupilumab and AR101-CODIT are investigational in this study, because they have not been approved by any health authority for marketing for the condition being studied. Dupilumab has been approved for other medical conditions. Dupilumab and AR101-CODIT are being studied for treatment of peanut allergy.
Patients may be eligible for this study if they are: 6 to 17 years (male or female) • Allergic to peanuts
This is not a complete list of eligibility criteria. Your doctor will review your child’s eligibility with you.
All study-related visits, tests, and procedures will be provided.
To learn more, talk to your child’s doctor or contact your local study site:
PEANUT ALLERGY STUDY